Acute ischemic stroke occurs when a clot or other obstruction cuts off blood flow through an artery supplying the brain. Neurons are exceptionally dependent on a continuous delivery of oxygen and glucose, so even a short interruption can trigger energy failure, cellular injury and, in severe cases, permanent tissue death. Modern treatments such as intravenous thrombolysis and mechanical thrombectomy aim to reopen the blocked vessel as quickly as possible, but many patients remain at risk of disability despite receiving current therapies. One reason is that restoring flow through a major artery does not automatically normalize the complex network of smaller vessels that controls how blood is distributed through damaged brain tissue. This regulatory system, called cerebral autoregulation, adjusts vascular resistance in response to changes in pressure and metabolic demand, helping protect the brain from both inadequate perfusion and excessive flow.

Remote ischemic conditioning is designed to stimulate protective responses beyond the limb where the cuff is applied. In the trial, participants received either the active intervention or a sham procedure twice each day for seven consecutive days. Active conditioning used cuff pressure of 200 millimeters of mercury, while the sham treatment used 60 millimeters of mercury. The protocol was therefore intended to create a meaningful temporary ischemic stimulus in the treatment group while preserving the appearance and routine of the procedure in the control group. The researchers enrolled patients with acute ischemic stroke between June 2023 and May 2024, randomly assigning 60 people to each group. Participants and the assessors responsible for the study endpoints were blinded in the trial design, reducing the chance that expectations would influence the principal measurements.

The primary outcome was cerebral blood-flow regulation seven days after randomization. Rather than simply asking how much blood moved through a brain artery at one instant, the investigators examined the relationship between fluctuations in arterial pressure and changes in cerebral blood flow. A central measure in this analysis was phase difference, expressed in degrees. In physiological terms, phase difference describes the timing offset between a pressure change and the resulting blood-flow response. When cerebral vessels actively adjust their diameter, changes in flow may lag behind changes in pressure in a characteristic pattern. A larger phase difference can therefore indicate more effective dynamic regulation, although its interpretation depends on the measurement method and the broader physiological context. The measure is especially useful because autoregulation is not a static state; it is an ongoing response system that must react continuously as circulation changes.

The difference between the two groups was statistically significant on both sides of the brain. On the affected side, the median phase difference was 36.84 degrees in the remote-conditioning group, with an interquartile range of 21.49 to 51.36 degrees, compared with 28.57 degrees in the sham group, whose interquartile range was 17.17 to 38.52 degrees. After adjustment, the estimated between-group effect was 11.336 degrees, with a 95 percent confidence interval from 4.523 to 18.149 and a P value of 0.001. On the unaffected side, the corresponding medians were 35.13 degrees for active treatment and 30.37 degrees for sham treatment. The adjusted effect was 11.780 degrees, with a 95 percent confidence interval from 4.260 to 19.300 and a P value of 0.002. The bilateral pattern suggests that the intervention’s influence was not confined to tissue immediately surrounding the original stroke.

The biological route by which a brief limb stimulus might influence the brain remains uncertain. Researchers have proposed several possibilities, including signaling through the nervous system, changes in circulating factors released during transient ischemia and alterations in the function of the vascular endothelium, the cell layer lining blood vessels. Repeated brief reductions in limb perfusion may also provoke systemic adaptations affecting inflammation, oxidative stress and vascular reactivity. None of these mechanisms was established by the trial itself, and the study was not designed to identify a single molecular pathway. Its contribution is more specific: it provides clinical evidence that remote ischemic conditioning is associated with a measurable improvement in the timing and responsiveness of cerebral blood-flow regulation during the early period after ischemic stroke. That physiological result may help guide future studies seeking to connect vascular regulation with tissue preservation and neurological recovery.

The treatment did not produce statistically significant differences in several secondary outcomes. Blood pressure, heart rate and blood-flow velocity in the middle cerebral artery were similar between the remote-conditioning and sham groups. The researchers also found no significant difference in 90-day scores on the modified Rankin Scale, a widely used measure of disability ranging from no symptoms to severe dependence or death. This distinction is crucial. Improved autoregulation may represent an intermediate mechanism that supports recovery, but a change in an intermediate physiological marker does not necessarily translate into a detectable improvement in functional outcome, particularly in a study of this size. Stroke recovery is shaped by many factors, including the location and volume of injury, age, baseline neurological severity, complications, rehabilitation and the speed and success of reperfusion treatment.

The findings also do not show that the cuff procedure can replace emergency stroke care or reopen a blocked artery. The study examined remote conditioning as a potential adjunct during the acute phase of illness, not as a standalone therapy. Its safety profile was encouraging: the intervention did not increase adverse events during hospitalization. Still, a 120-person trial from a single research setting cannot establish how well the approach would perform across different hospitals, stroke subtypes, treatment pathways or patient populations. Larger trials would need to determine whether the improvement in cerebral blood-flow regulation is reproducible, whether it persists beyond the seven-day treatment period and whether it predicts meaningful benefits in cognition, mobility, independence or quality of life. They would also need to clarify the optimal cuff pressure, timing, duration and number of conditioning cycles, as well as whether patients treated with clot-dissolving drugs or thrombectomy respond differently.

For now, the study presents remote ischemic conditioning as a promising physiological intervention rather than a proven way to improve survival or reduce disability. The appeal of the approach lies in its simplicity: it uses equipment familiar to every clinic, can be administered repeatedly and targets the body’s vascular control systems without requiring direct access to the brain. Yet the most important result is not that a cuff appears to make cerebral blood flow rise. The researchers observed a more nuanced change in how brain circulation responds to pressure fluctuations, suggesting that the injured cerebrovascular system may retain the capacity to become more responsive after stroke. If future studies confirm that this restored regulation protects vulnerable tissue or improves rehabilitation outcomes, remote conditioning could become a practical addition to stroke care. Until then, the new evidence supports further investigation while leaving the decisive clinical question—whether better blood-flow regulation leads to better lives—unanswered.

Atorvastatin, widely known for its cholesterol-lowering properties, has garnered increasing attention for its pleiotropic effects in the central nervous system. Prior studies have hinted at its ability to modulate neuroinflammation and enhance cerebral blood flow, but the underlying molecular details had remained elusive. In this latest investigation, the authors employed a naturally aging rat model to closely mimic human aging, which is pivotal given the complexity and multifactorial nature of cognitive deterioration in elderly populations. Their strategic use of this model allowed for the observation of atorvastatin’s effects over an extended period, revealing sustained cognitive benefits that correlate with biochemical modifications in neuronal structures.

Central to the study’s findings is the dynamic interplay between lysine crotonylation and ubiquitination at position 272 on the NFL protein. NFL, a fundamental component of the neuronal cytoskeleton, is integral to maintaining axonal integrity and facilitating proper nerve signal conduction. Modifications at the lysine 272 residue appear to act as molecular switches that regulate NFL’s stability and turnover. The researchers discovered that atorvastatin increases SIRT2-mediated decrotonylation at this site, which subsequently promotes ubiquitination. This orchestrated transition facilitates the clearance of damaged NFL proteins, thereby preserving cytoskeletal architecture and enhancing neuronal resilience.

SIRT2, a member of the sirtuin family of NAD+-dependent deacylases, emerges in this study as a pivotal enzymatic regulator orchestrating this modification cascade. Previous literature has established SIRT2’s involvement in neurodegeneration and metabolic regulation, but this particular study delves deeper into its nuanced role in modulating post-translational modifications relevant to aging neurons. By enhancing SIRT2’s de-crotonylase activity, atorvastatin appears to fine-tune the balance between protein modification states, enabling more effective proteasomal degradation of damaged or dysfunctional NFL molecules.

What makes these findings particularly compelling is the link between molecular modulation and actual cognitive improvements observed in the aging rats. Behavioral assays conducted over the duration of the study documented significant enhancements in memory, learning, and spatial navigation among atorvastatin-treated subjects compared to controls. This provides strong evidence that targeting the SIRT2-NFL modification axis does not merely represent an abstract biochemical phenomenon but translates into tangible neurocognitive benefits with potential clinical significance.

Further biochemical analyses revealed that untreated aging rats exhibited elevated levels of lysine 272 crotonylation on NFL alongside diminished ubiquitination, correlating with increased accumulation of misfolded NFL aggregates. These aggregates are hypothesized to disrupt axonal transport and synaptic function, underpinning various cognitive deficits. Atorvastatin treatment reversed this pattern, amplifying ubiquitination and promoting clearance of these neurotoxic protein forms, emphasizing the drug’s role in maintaining protein homeostasis through post-translational modification dynamics.

The study also addressed the broader implications of SIRT2’s role in cellular aging. Beyond its well-established functions in metabolic sensing and gene expression regulation, SIRT2’s involvement in modulating the proteostasis network represents an exciting frontier. The ability of atorvastatin to upregulate this pathway hints at potential cross-talk between lipid metabolism modulators and epigenetic-like enzyme activities, opening avenues for novel polypharmacological strategies to mitigate aging-related neurodegeneration.

This intersection between lipid-lowering therapies and epigenetic regulation of neuronal proteins represents a paradigm shift in understanding how systemic pharmacological interventions can impact brain aging. It positions atorvastatin as a candidate drug for repurposing in neurodegenerative therapeutics, especially considering its known safety profile and extensive clinical use. However, important questions remain regarding dosage optimization, the precise timing of intervention, and long-term consequences on neuronal function that subsequent studies will need to address.

Intriguingly, the research team also speculated on the possibility that modulating post-translational modifications on NFL might influence the interaction dynamics with other neurofilament subunits and associated cytoskeletal components. Such changes could have ripple effects on axonal transport efficiency and synaptic connectivity, hallmarks that degenerate in multiple neurodegenerative diseases including Alzheimer’s and Parkinson’s disorders. Thus, refining our understanding of these molecular switches might yield broader implications for neurobiology and aging research.

Moreover, the utilization of cutting-edge mass spectrometry techniques allowed for precise quantification and localization of lysine crotonylation and ubiquitination marks, providing an unprecedented molecular resolution. The rigorous temporal characterization of these modifications throughout the treatment timeline adds a dynamic dimension, underscoring that the post-translational landscape is fluid and tightly regulated during pharmacological intervention.

The significance of this study extends beyond the immediate context of atorvastatin and aging rats. It adds to a growing body of evidence affirming the importance of reversible acylations, such as crotonylation, in regulating protein function in health and disease. Unlike more traditional post-translational modifications, crotonylation is just beginning to be explored, and its dynamic crosstalk with ubiquitination suggests an intricate regulatory network poised to be a fertile ground for novel therapeutic approaches.

As the global population ages, the quest to preserve cognitive vitality takes on increasing urgency. With this study, the prospect of using a widely available drug to harness endogenous enzymatic machinery for proteome maintenance could represent a major stride forward. It also underscores the critical role of fundamental research in revealing unexpected drug actions and biological pathways that may translate into impactful clinical interventions.

While the results are promising, the authors are cautious in their interpretation and emphasize the necessity for subsequent validation in primate models and eventually human clinical trials. They advocate for integrative studies combining molecular biology, neuroimaging, and cognitive assessment to fully unravel the mechanistic underpinnings and therapeutic potential of targeting the SIRT2-crotonylation-ubiquitination axis.

In conclusion, this innovative study bridges pharmacology, epigenetics, and neurobiology to illuminate a previously unrecognized mechanism by which atorvastatin may confer neurocognitive benefits during aging. The discovery that SIRT2-mediated modulation of NFL lysine 272 crotonylation to ubiquitination enhances cognitive function opens new vistas in the development of therapeutic strategies aimed at ameliorating age-associated cognitive decline. As such, it invites a reassessment of the broader potential of statins beyond cardiovascular health and stimulates enthusiasm for further investigation into the complex regulatory networks governing neuronal longevity and plasticity.

Subject of Research: The study investigates the molecular mechanisms underlying the cognitive improvement induced by long-term atorvastatin treatment, focusing on the modulation of SIRT2-mediated dynamic transitions between lysine 272 crotonylation and ubiquitination on neurofilament light chain (NFL) in naturally aging rats.

Article Title: Long-term atorvastatin improves cognitive function by modulating SIRT2-mediated dynamic transition of NFL lysine 272 crotonylation to ubiquitination in naturally aging rats.

Article References:
Xu, TC., Cai, JR. & Chen, HS. Long-term atorvastatin improves cognitive function by modulating SIRT2-mediated dynamic transition of NFL lysine 272 crotonylation to ubiquitination in naturally aging rats. Cell Death Discov. 11, 463 (2025). https://doi.org/10.1038/s41420-025-02764-7

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02764-7